{"disease":{"id":"all-neoplasms","name":"all neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03510923","title":"Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy","phase":"","overall_status":"COMPLETED","enrollment_count":17380,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT04140552","title":"Chinese Research Group of Gallbladder Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06223763","title":"SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT06276153","title":"Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03740165","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1367,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03038100","title":"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1301,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06494241","title":"Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06131840","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":914,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03872362","title":"Radiomics Multifactorial Biomarker for Pulmonary Nodules","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05116189","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":643,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":615,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01846611","title":"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":581,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04111978","title":"MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Swiss GO Trial Group","has_results":false},{"nct_id":"NCT06376084","title":"Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":532,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05896956","title":"The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03134872","title":"A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":419,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05647122","title":"First in Human Study of AZD9592 in Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":403,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04699188","title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":344,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04429087","title":"A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03468426","title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04794322","title":"Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05194072","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":250,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05675605","title":"A Study of TY-1091 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":248,"lead_sponsor_name":"TYK Medicines, Inc","has_results":false},{"nct_id":"NCT04222972","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04579380","title":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":217,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":true},{"nct_id":"NCT07489339","title":"MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Shanxi Province Cancer Hospital","has_results":false},{"nct_id":"NCT03396445","title":"Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03817866","title":"Chromogranin A as Blood Marker in Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Brahms AG","has_results":false},{"nct_id":"NCT05882058","title":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT01478685","title":"A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03593681","title":"Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT03085069","title":"A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":146,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03648489","title":"Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT07489066","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06003231","title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}